Fabio Lopez
Direktor/Vorstandsmitglied bei Sellas Life Sciences Group Ltd.
Profil
Fabio Lopez is currently a Director at Sellas Life Sciences Group Ltd.
He was previously a Director at SELLAS Life Sciences Group, Inc. from 2017 to 2018.
Aktive Positionen von Fabio Lopez
| Unternehmen | Position | Beginn |
|---|---|---|
Sellas Life Sciences Group Ltd.
 Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | Direktor/Vorstandsmitglied | 29.12.2017 |
Ehemalige bekannte Positionen von Fabio Lopez
| Unternehmen | Position | Ende |
|---|---|---|
| SELLAS LIFE SCIENCES GROUP, INC. | Direktor/Vorstandsmitglied | 27.07.2018 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SELLAS LIFE SCIENCES GROUP, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Sellas Life Sciences Group Ltd.
Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | Health Technology |
